|
1
|
Mudhar HS, Parsons MA, Sisley K, Rundle P,
Singh A and Rennie IG: A critical appraisal of the prognostic and
predictive factors for uveal malignant melanoma. Histopathology.
45:1–12. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Singh AD and Borden EC: Metastatic uveal
melanoma. Ophthalmol Clin North Am. 18:143–150. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Desjardins L, Levy-Gabriel C,
Lumbroso-Lerouic L, Sastre X, Dendale R, Couturier J,
Piperno-Neumann S, Dorval T, Mariani P, Salmon R, et al: Prognostic
factors for malignant uveal melanoma. Retrospective study on 2,241
patients and recent contribution of monosomy-3 research. J Fr
Ophtalmol. 29:741–749. 2006.In French. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kembhavi AA, Buttle DJ, Knight CG and
Barrett AJ: The two cysteine endopeptidases of legume seeds:
Purification and characterization by use of specific fluorometric
assays. Arch Biochem Biophys. 303:208–213. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dalton JP, Hola-Jamriska L and Brindley
PJ: Asparaginyl endopeptidase activity in adult Schistosoma
mansoni. Parasitology. 111:575–580. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen JM, Dando PM, Rawlings ND, Brown MA,
Young NE, Stevens RA, Hewitt E, Watts C and Barrett AJ: Cloning,
isolation and characterization of mammalian legumain, an
asparaginyl endopeptidase. J Biol Chem. 272:8090–8098. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu C, Sun C, Huang H, Janda K and
Edgington T: Overexpression of legumain in tumors is significant
for invasion/metastasis and a candidate enzymatic target for
prodrug therapy. Cancer Res. 63:2957–2964. 2003.PubMed/NCBI
|
|
8
|
Murthy RV, Arbman G, Gao J, Roodman GD and
Sun XF: Legumain expression in relation to clinicopathologic and
biological variables in colorectal cancer. Clin Cancer Res.
11:2293–2299. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gawenda J, Traub F, Lück HJ, Kreipe H and
von Wasielewski R: Legumain expression as a prognostic factor in
breast cancer patients. Breast Cancer Res Treat. 102:1–6. 2007.
View Article : Google Scholar
|
|
10
|
Barrett AJ and Rawlings ND: Evolutionary
lines of cysteine peptidases. Biol Chem. 382:727–733. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen JM, Fortunato M, Stevens RA and
Barrett AJ: Activation of progelatinase A by mammalian legumain, a
recently discovered cysteine proteinase. Biol Chem. 382:777–783.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Luo Y, Zhou H, Krueger J, Kaplan C, Lee
SH, Dolman C, Markowitz D, Wu W, Liu C, Reisfeld RA and Xiang R:
Targeting tumor-associated macrophages as a novel strategy against
breast cancer. J Clin Invest. 116:2132–2141. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lewēn S, Zhou H, Hu HD, Cheng T, Markowitz
D, Reisfeld RA, Xiang R and Luo Y: A legumain-based minigene
vaccine targets the tumor stroma and suppresses breast cancer
growth and angiogenesis. Cancer Immunol Immunother. 57:507–515.
2008. View Article : Google Scholar
|
|
14
|
Xiang R, Luo Y, Niethammer AG and Reisfeld
RA: Oral DNA vaccines target the tumor vasculature and
microenvironment and suppress tumor growth and metastasis. Immunol
Rev. 222:117–128. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bajjuri KM, Liu Y, Liu C and Sinha SC: The
legumain protease-activated auristatin prodrugs suppress tumor
growth and metastasis without toxicity. Chem Med Chem. 6:54–59.
2011. View Article : Google Scholar
|
|
16
|
Wu W, Luo Y, Sun C, et al: Targeting
cell-impermeable prodrug activation to tumor microenvironment
eradicates multiple drug-resistant neoplasms. Cancer Res.
66:970–980. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stern L, Perry R, Ofek P, Many A, Shabat D
and Satchi-Fainaro R: A novel antitumor prodrug platform designed
to be cleaved by the endoprotease legumain. Bioconjug Chem.
20:500–510. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Seftor EA, Meltzer PS, Kirschmann DA,
Pe'er J, Maniotis AJ, Trent JM, Folberg R and Hendrix MJ: Molecular
determinants of human uveal melanoma invasion and metastasis. Clin
Exp Metastasis. 19:233–246. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
20
|
Briggs JJ, Haugen MH, Johansen HT, Riker
AI, Abrahamson M, Fodstad Ø, Maelandsmo GM and Solberg R: Cystatin
E/M suppresses legumain activity and invasion of human melanoma.
BMC Cancer. 10:172010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Andrade V, Guerra M, Jardim C, Melo F,
Silva W, Ortega JM, Robert M, Nathanson MH and Leite F:
Nucleoplasmic calcium regulates cell proliferation through
legumain. J Hepatol. 55:626–635. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bingle L, Brown NJ and Lewis CE: The role
of tumour-associated macrophages in tumour progression:
Implications for new anticancer therapies. J Pathol. 196:254–265.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Clerin V, Shih HH, Deng N, Hebert G,
Resmini C, Shields KM, Feldman JL, Winkler A, Albert L, Maganti V,
et al: Expression of the cysteine protease legumain in vascular
lesions and functional implications in atherogenesis.
Atherosclerosis. 201:53–66. 2008. View Article : Google Scholar : PubMed/NCBI
|
